JPMorgan analyst Richard Vosser raised the firm’s price target on Novartis to CHF 95 from CHF 92 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVS:
- IO Biotech appoints Qasim Ahmad MD, CMO, Faulkner CTO
- Novartis (NYSE:NVS) Gains on Q2 Beat; Boosts Outlook
- Novartis raises FY23 group sales ex-Sandoz view to high single digits
- Novartis board endorses separation of Sandoz by way of 100% spinoff
- Novartis initiates up to $15B share buyback, to be completed by year-end 2025